Pir, s-7701    (DrugBank: -)

1 disease
告示番号疾患名(ページ内リンク)臨床試験数
85特発性間質性肺炎5

85. 特発性間質性肺炎 [臨床試験数:514,薬物数:377(DrugBank:108),標的遺伝子数:97,標的パスウェイ数:204
Searched query = "Idiopathic interstitial pneumonia", "IIPs", "Idiopathic pulmonary fibrosis", "IPF", "Usual interstitial pneumonia", "UIP", "Non-specific interstitial pneumonia", "NSIP", "Acute interstitial pneumonia", "AIP", "Diffuse alveolar damage", "DAD", "COP", "Organizing pneumonia", "OP", "Desquamative interstitial pneumonia", "DIP", "Respiratory bronchiolitis - associated interstitial lung disease", "RB-ILD", "Lymphocytic interstitial pneumonia", "LIP"
The queries were searched in Public_title, Scientific_title, and Condition. Export date: 03/15/2021. Trials are sorted by Date_enrollment from most recent to oldest in the table.
5 / 514 trials found
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1EUCTR2007-007800-13-IE
(EUCTR)
04/06/200807/02/2008An Open-Label Extension Study of the Long-Term Safety of Pirfenidone in Patients with Idiopathic Pulmonary Fibrosis (IPF) Who Complete the CAPACITY Studies - Open-Label Extension of Pirfenidone CAPACITY StudiesAn Open-Label Extension Study of the Long-Term Safety of Pirfenidone in Patients with Idiopathic Pulmonary Fibrosis (IPF) Who Complete the CAPACITY Studies - Open-Label Extension of Pirfenidone CAPACITY Studies Idiopathic Pulmonary Fibrosis (IPF)
MedDRA version: 9.1;Level: LLT;Classification code 10021240;Term: Idiopathic pulmonary fibrosis
Product Name: Pirfenidone
INN or Proposed INN: Pirfenidone
Other descriptive name: PIR, S-7701
InterMune, Inc.NULLNot RecruitingFemale: yes
Male: yes
750Phase 3France;Belgium;Germany;Italy;United Kingdom;Ireland;Spain
2EUCTR2007-007800-13-ES
(EUCTR)
26/05/200801/04/2008An Open-Label Extension Study of the Long-Term Safety of Pirfenidone in Patients with Idiopathic Pulmonary Fibrosis (IPF) Who Complete the CAPACITY StudiesEstudio de extensión de etiqueta abierta de la seguridad a largo plazo de pirfenidona en pacientes con fibrosis pulmonar idiopática (FPI) que completan los estudios CAPACITY. - Open-Label Extension of Pirfenidone CAPACITY StudiesAn Open-Label Extension Study of the Long-Term Safety of Pirfenidone in Patients with Idiopathic Pulmonary Fibrosis (IPF) Who Complete the CAPACITY StudiesEstudio de extensión de etiqueta abierta de la seguridad a largo plazo de pirfenidona en pacientes con fibrosis pulmonar idiopática (FPI) que completan los estudios CAPACITY. - Open-Label Extension of Pirfenidone CAPACITY Studies Idiopathic Pulmonary Fibrosis (IPF)Fibrosis pulmonar idiopática
MedDRA version: 9.1;Level: LLT;Classification code 10021240;Term: Idiopathic pulmonary fibrosis
Product Name: Pirfenidone
INN or Proposed INN: Pirfenidone
Other descriptive name: PIR, S-7701
InterMune, Inc.NULLNot RecruitingFemale: yes
Male: yes
750Phase 3France;Belgium;Spain;Ireland;Germany;Italy;United Kingdom
3EUCTR2007-007800-13-DE
(EUCTR)
23/05/200821/02/2008An Open-Label Extension Study of the Long-Term Safety of Pirfenidone in Patients with Idiopathic Pulmonary Fibrosis (IPF) Who Complete the CAPACITY Studies - Open-Label Extension of Pirfenidone CAPACITY StudiesAn Open-Label Extension Study of the Long-Term Safety of Pirfenidone in Patients with Idiopathic Pulmonary Fibrosis (IPF) Who Complete the CAPACITY Studies - Open-Label Extension of Pirfenidone CAPACITY Studies Idiopathic Pulmonary Fibrosis (IPF)
MedDRA version: 9.1;Level: LLT;Classification code 10021240;Term: Idiopathic pulmonary fibrosis
Product Name: Pirfenidone
INN or Proposed INN: Pirfenidone
Other descriptive name: PIR, S-7701
InterMune, Inc.NULLNot RecruitingFemale: yes
Male: yes
750Phase 3France;Spain;Belgium;Ireland;Germany;Italy;United Kingdom
4EUCTR2007-007800-13-BE
(EUCTR)
15/05/200826/03/2008An Open-Label Extension Study of the Long-Term Safety of Pirfenidone in Patients with Idiopathic Pulmonary Fibrosis (IPF) Who Complete the CAPACITY Studies - Open-Label Extension of Pirfenidone CAPACITY StudiesAn Open-Label Extension Study of the Long-Term Safety of Pirfenidone in Patients with Idiopathic Pulmonary Fibrosis (IPF) Who Complete the CAPACITY Studies - Open-Label Extension of Pirfenidone CAPACITY Studies Idiopathic Pulmonary Fibrosis (IPF)
MedDRA version: 9.1;Level: LLT;Classification code 10021240;Term: Idiopathic pulmonary fibrosis
Product Name: Pirfenidone
INN or Proposed INN: Pirfenidone
Other descriptive name: PIR, S-7701
InterMune, Inc.NULLNot RecruitingFemale: yes
Male: yes
750France;Spain;Belgium;Ireland;Germany;Italy;United Kingdom
5EUCTR2006-000252-41-IT
(EUCTR)
27/09/200630/08/2006A randomized, Double-Blind, Placebo-Controlled, Phase 3, Three-Arm Study of the Safety and Efficacy of Pirferidone in patients with Idiopathic Pulmonary Fibrosis - NDA randomized, Double-Blind, Placebo-Controlled, Phase 3, Three-Arm Study of the Safety and Efficacy of Pirferidone in patients with Idiopathic Pulmonary Fibrosis - ND Idiopathic pulmonary fibrosis IPF ICD X J84.1other interstitial pulmonary
MedDRA version: 6.1;Level: PT;Classification code 10037383
Product Name: PIR, S-7701INTERMUNENULLNot RecruitingFemale: yes
Male: yes
325Phase 3United Kingdom;Italy